Initiation of research: Disrupting current blood disease therapy
Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.
24 Jan 19
Northland Capital Partners Research and Daily Commentaries
Research Tree offers Northland Capital Partners research, providing ongoing coverage of 246 shares. We offer 755 reports from Northland Capital Partners on Research Tree.
Research reports provided by Northland Capital Partners
Companies covered by Northland Capital Partners
Sectors covered by Northland Capital Partners